This week saw two $250 million-plus initial public offering (IPO) filings for Neumora Therapeutics and RayzeBio, plus a record third-round financing for Generate Biomedici
Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as 'junk' – for hidden treasure.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh